All Pharma News
UniQure Announces Data of Phase I/II Trials of AMT-130 for Huntington Disease

UniQure Announces Data of Phase I/II Trials of AMT-130 for Huntington Disease
GLOBENEWSWIRE
09 Jul 2024
Share Share
Genezen to Acquire uniQure’s Commercial Gene Therapy Operations in Lexington

Genezen to Acquire uniQure’s Commercial Gene Therapy Operations in Lexington
CONTRACT PHARMA
02 Jul 2024
Share Share
UniQure, with sale of plant, outsources Hemgenix manufacturing

UniQure, with sale of plant, outsources Hemgenix manufacturing
Ned Pagliarulo BIOPHARMADIVE
02 Jul 2024
Share Share
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
GLOBENEWSWIRE
01 Jul 2024
Share Share
uniQure`s AMT-130 Gene Therapy Gets RMAT For Huntington`s Disease

uniQure`s AMT-130 Gene Therapy Gets RMAT For Huntington`s Disease
GLOBENEWSWIRE
03 Jun 2024
Share Share
uniQure Announces Q1 2024 Results And Company Progress

uniQure Announces Q1 2024 Results And Company Progress
GLOBENEWSWIRE
07 May 2024
Share Share
Kyowa`s Orchard hopes $4.25M gene therapy price tag bears fruit

Kyowa`s Orchard hopes $4.25M gene therapy price tag bears fruit
Fraiser Kansteiner FIERCE PHARMA
20 Mar 2024
Share Share
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
GLOBENEWSWIRE
28 Feb 2024
Share Share
CSL and uniQure unveil three-year data for one-time hemophilia B gene therapy

CSL and uniQure unveil three-year data for one-time hemophilia B gene therapy
ENDPTS
09 Feb 2024
Share Share
Uniqure Huntington`s gene therapy data `on the favorable side`

Uniqure Huntington`s gene therapy data `on the favorable side`
Annalee Armstrong FIERCE BIOTECH
20 Dec 2023
Share Share